News

Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is...

Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print, demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death...

Labcorp, a leading global life sciences company, announced that it is now offering clonoSEQ®, the first U.S. Food and Drug Administration (FDA)-cleared test that can identify whether cancer cells remain in a patient’s body during and after treatment for...

AstraZeneca PLC said that its Imfinzi immunotherapy treatment for extensive-stage small-cell lung cancer has been approved in China for first-line treatment of adult patients, in combination with chemotherapy. The pharmaceutical company said the approval by China's National Medical Products Administration...

Aptamer Group, the developer of Optimer therapeutics and diagnostics, and WuXi AppTec Research Service Division, an integrated chemistry and biology research platform, announce a research collaboration to identify new Optimer-enabled therapeutics. The collaboration will aim to identify Optimers for use...

Manufacturing and scale-up of industrialized processes to manufacture gene therapy products are accompanied by many challenges that must be overcome to succeed in the marketplace. Commercialization of gene therapies for patient use is time consuming and requires substantial financial...

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that Paraguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with...